Literature DB >> 8713980

Identification of agonist binding sites of vasopressin and oxytocin receptors.

B Mouillac1, B Chini, M N Balestre, S Jard, C Barberis, M Manning, E Tribollet, S Trumpp-Kallmeyer, J Hoflack, J Elands.   

Abstract

The present study aims at delineating residues in the vasopressin/oxytocin receptor family responsible for the high affinity binding of the hormone. Therefore, we have constructed a computer-generated 3 dimensional model of the rat V1a vasopressin receptor subtype which allowed us to propose residues likely to be involved in agonist binding. Among these residues, several are highly conserved in the receptor family. They were selected for site-directed mutagenesis on the basis of putative direct interaction with bound ligands. The present model and experimental results led us to conclude that the hormone is docked in a pocket completely buried in the transmembrane core of the receptor. Large polar residues, such as glutamine and lysine, located in transmembrane regions 2,3,4 and 6 are involved in the binding of the neurohypophysial hormone. Since all the mutated residues are highly conserved in AVP and OT receptors, we propose that the agonist binding site is similar in all members of the receptor family; only minor changes were found in antagonist potencies, suggesting that agonist and antagonist binding sites do not completely overlap.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 8713980

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  9 in total

1.  Identification of avian vasotocin receptor subtype-specific antagonists involved in the stress response of the chicken, Gallus gallus.

Authors:  Seong W Kang; Srinivas Jayanthi; Gurueswar Nagarajan; Thallapuranam Krishnaswamy Suresh Kumar; Wayne J Kuenzel
Journal:  J Biomol Struct Dyn       Date:  2018-05-17

Review 2.  Fluorescent agonists and antagonists for vasopressin/oxytocin G protein-coupled receptors: usefulness in ligand screening assays and receptor studies.

Authors:  B Mouillac; M Manning; T Durroux
Journal:  Mini Rev Med Chem       Date:  2008-09       Impact factor: 3.862

Review 3.  Oxytocin in the Male Reproductive Tract; The Therapeutic Potential of Oxytocin-Agonists and-Antagonists.

Authors:  Beatrix Stadler; Michael R Whittaker; Betty Exintaris; Ralf Middendorff
Journal:  Front Endocrinol (Lausanne)       Date:  2020-10-22       Impact factor: 5.555

Review 4.  Vasopressin and oxytocin receptor systems in the brain: Sex differences and sex-specific regulation of social behavior.

Authors:  Kelly M Dumais; Alexa H Veenema
Journal:  Front Neuroendocrinol       Date:  2015-05-04       Impact factor: 8.606

5.  Nanoparticle encapsulated oxytocin increases resistance to induced seizures and restores social behavior in Scn1a-derived epilepsy.

Authors:  Jennifer C Wong; Lindsey Shapiro; Jacquelyn T Thelin; Elizabeth C Heaton; Rokon U Zaman; Martin J D'Souza; Kevin S Murnane; Andrew Escayg
Journal:  Neurobiol Dis       Date:  2020-10-25       Impact factor: 5.996

6.  Oxytocin reduces cocaine seeking and reverses chronic cocaine-induced changes in glutamate receptor function.

Authors:  Luyi Zhou; Wei-Lun Sun; Amy B Young; Kunhee Lee; Jacqueline F McGinty; Ronald E See
Journal:  Int J Neuropsychopharmacol       Date:  2014-10-31       Impact factor: 5.176

7.  Early experiences can alter the size of cortical fields in prairie voles (Microtus ochrogaster).

Authors:  A M H Seelke; S-M Yuan; A M Perkeybile; L A Krubitzer; K L Bales
Journal:  Environ Epigenet       Date:  2016-10-20

8.  Expanding the versatility and scope of the oxime ligation: rapid bioconjugation to disulfide-rich peptides.

Authors:  Anke Hering; Nayara Braga Emidio; Markus Muttenthaler
Journal:  Chem Commun (Camb)       Date:  2022-08-11       Impact factor: 6.065

9.  Helping oxytocin deliver: considerations in the development of oxytocin-based therapeutics for brain disorders.

Authors:  K Macdonald; D Feifel
Journal:  Front Neurosci       Date:  2013-03-15       Impact factor: 4.677

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.